Results from the phase III SPOTLIGHT trial show that the investigational mAb zolbetuximab plus chemotherapy improves progression-free survival and overall survival in patients newly diagnosed with claudin 18.2-positive, HER2-negative locally advanced inoperable or metastatic gastric or gastroesophageal junction cancer. The drug could become a standard treatment option for these patients.
©2023 American Association for Cancer Research.